Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenzhen Univ. C1qbp compound cinerealactam B
- Development stage
- Preclinical
- Lead developer
- Shenzhen University
01
Overview
Shenzhen Univ. C1qbp compound cinerealactam B: sourced facts only. name: "Subsequently, C1qbp knockdown using siRNA allowed us to validate the target protein of 3." [PMID:38330722]; target: "Subsequently, C1qbp knockdown using siRNA allowed us to validate the target protein of 3." [PMID:38330722]; developer: "Institute for Inheritance-Based Innovation of Chinese Medicine, School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, Guangdong, PR China." [PMID:38330722]; stage: "Biological evaluation of compounds 1-4 showed that 3 displays anti-renal fibrotic activities in TGF-β1 induced NRK-52e cells." [PMID:38330722]
02
Targets
C1QBP (Globular C1q receptor)
Beyond the preview
Go deeper on Shenzhen Univ. C1qbp compound cinerealactam B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Univ. C1qbp compound cinerealactam B.